RCUS - Arcus Biosciences, Inc.

QQQ $ 455.25 $ 5.77 (1.29 %)

DIA $ 409.08 $ 4.58 (1.13 %)

SPY $ 546.60 $ 6.05 (1.12 %)

TLT $ 99.96 $ 0.43 (0.43 %)

GLD $ 231.58 $ 0.97 (0.42 %)

Previous Close

$ 16.31

Open

Bid

$ 16.29 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 12.95 - $ 21.79

Volume

539,153

Average Volume

Market Cap

1.49B

Beta (5Y Monthly)

$ 1.35

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-21-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-07-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-02-2022	09-30-2022	10-Q
9	08-03-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	02-23-2022	12-31-2021	10-K
12	11-08-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-05-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-05-2020	03-31-2020	10-Q
19	03-05-2020	12-31-2019	10-K
20	11-05-2019	09-30-2019	10-Q
21	08-06-2019	06-30-2019	10-Q
22	05-02-2019	03-31-2019	10-Q
23	03-05-2019	12-31-2018	10-K
24	11-08-2018	09-30-2018	10-Q
25	08-06-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Breaking Down Arcus Biosciences: 4 Analyst...
08/09/2024 16:00:31

Cantor Fitzgerald Reiterates Overweight on...
08/09/2024 15:11:37

Cantor Fitzgerald analyst Li Watsek reiterates Arcus Biosciences (NYSE:RCUS) with a Overweight.

Wedbush Reiterates Outperform on Arcus Bio...
08/09/2024 13:32:17

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.

Arcus Biosciences Q2 2024 GAAP EPS $(1.02)...
08/08/2024 20:10:54

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.1...

Arcus Biosciences Says Taiho Exercised Its...
07/08/2024 22:07:11

This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is ...

Cracking The Code: Understanding Analyst R...
07/08/2024 21:00:49

Barclays Maintains Overweight on Arcus Bio...
07/08/2024 19:59:31

Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $35...

Cantor Fitzgerald Reiterates Overweight on...
07/05/2024 16:15:18

Cantor Fitzgerald analyst Alethia Young reiterates Arcus Biosciences (NYSE:RCUS) with a Overweight.

Truist Securities Maintains Buy on Arcus B...
06/24/2024 13:43:23

Truist Securities analyst Asthika Goonewardene maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price targe...

Arcus Biosciences In Collaboration With Gi...
06/10/2024 12:38:47

Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to b...

after-disappointing-bladder-cancer-data-gilead-announces-encouraging-data-from-gastric-colorectal-cancer-studies

After Disappointing Bladder Cancer Data, G...
06/03/2024 16:35:14

Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cance...

Citigroup Maintains Buy on Arcus Bioscienc...
06/03/2024 15:13:11

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $36 ...

Gilead And Arcus Announced Etrumadenant Pl...
06/02/2024 14:36:05

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a ...

12-health-care-stocks-moving-in-fridays-pre-market-session

12 Health Care Stocks Moving In Friday's P...
05/24/2024 12:07:16

Wedbush Reiterates Outperform on Arcus Bio...
05/09/2024 12:50:31

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.

Arcus Biosciences Q1 2024 GAAP EPS $(0.05)...
05/08/2024 21:31:37

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.9...

Arcus Biosciences To Present New Data From...
04/24/2024 20:02:16

Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancer...

Navigating 5 Analyst Ratings For Arcus Bio...
03/25/2024 16:01:09

Truist Securities Reiterates Buy on Arcus ...
03/25/2024 15:54:56

Truist Securities analyst Robyn Karnauskas reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and maintains $50 price target.

Critical Insights From Arcus Biosciences A...
02/22/2024 14:00:14